Effects of histamine H1 receptor signaling on glucocorticoid receptor activity. Role of canonical and non-canonical pathways by Zappia, Carlos Daniel et al.
1Scientific RepoRts | 5:17476 | DOI: 10.1038/srep17476
www.nature.com/scientificreports
Effects of histamine H1 receptor 
signaling on glucocorticoid 
receptor activity. Role of canonical 
and non-canonical pathways
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Carlos Davio1,4, Carlos P. Fitzsimons3,* & Federico Monczor1,4,*
Histamine H1 receptor (H1R) antagonists and glucocorticoid receptor (GR) agonists are used to treat 
inflammatory conditions such as allergic rhinitis, atopic dermatitis and asthma. Consistent with the 
high morbidity levels of such inflammatory conditions, these receptors are the targets of a vast 
number of approved drugs, and in many situations their ligands are co-administered. However, this 
drug association has no clear rationale and has arisen from clinical practice. We hypothesized that 
H1R signaling could affect GR-mediated activity, impacting on its transcriptional outcome. Indeed, 
our results show a dual regulation of GR activity by the H1R: a potentiation mediated by G-protein 
βγ subunits and a parallel inhibitory effect mediated by Gαq-PLC pathway. Activation of the H1R by 
its full agonists resulted in a composite potentiating effect. Intriguingly, inactivation of the Gαq-PLC 
pathway by H1R inverse agonists resulted also in a potentiation of GR activity. Moreover, histamine 
and clinically relevant antihistamines synergized with the GR agonist dexamethasone to induce 
gene transactivation and transrepression in a gene-specific manner. Our work provides a delineation 
of molecular mechanisms underlying the widespread clinical association of antihistamines and GR 
agonists, which may contribute to future dosage optimization and reduction of well-described side 
effects associated with glucocorticoid administration.
Inflammation-related diseases present a great challenge in current medicine due to, among other factors, 
their high morbidity. Consistently, the histamine H1 receptor (H1R) and the glucocorticoid receptor 
(GR) are targets with the most number of drugs approved1, and they’re often used in combination ther-
apies2,3. Glucocorticoids (GC) are highly effective in combating inflammation in the context of a vari-
ety of diseases, such as asthma, allergic rhinitis (AR), atopic dermatitis (AD) and rheumatoid arthritis 
(RA)4. GC are involved in critical processes such as growth, reproduction, central nervous system and 
cardiovascular functions and immune and inflammatory actions as well as cell proliferation and survival. 
Their anti-inflammatory and immunomodulatory effects make these steroids the standard therapy to 
treat numerous autoimmune, inflammatory and allergic disorders, such as, asthma, rheumatoid arthritis 
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and AR among others. Unfortunately, chronic exposure to these agents becomes a problem for therapy 
resulting in a wide set of undesirable effects5.
There are different possible approaches to improve GC’s beneficial/adverse effect ratio, going from 
chemical optimization to the development of selective glucocorticoid receptor agonists (SEGRAs) based 
on the assumption that ligands which only induce gene transrepression and not transactivation should 
have a better therapeutic profile. Alternatively, add-on therapies present another way to control adverse 
effects by reducing GC dose and combining it with a different drug with anti-inflammatory activity.
In most tissues, both the beneficial and the adverse effects of GC are dose-dependent and mediated by 
activation of the GR6. The GR is a ligand-activated transcription factor, which once activated by hormone 
binding, homodimerizes, translocates to the nucleus and binds to specific target sequences in the DNA, 
called GC-response elements (GREs), thereby modulating gene transcription7. However, transrepression 
and transactivation of specific genes induces beneficial and adverse effects, respectively. Traditionally, it 
has been accepted that GC’s anti-inflammatory activity may be due to GR interaction with transcrip-
tion factors, e.g. NF-κ B, and inhibition of gene expression (transrepression), while the activation of 
gene transcription by GR binding to GREs (transactivation) may be responsible of metabolic effects and 
adverse effects at pharmacological doses6,8,9. However, new insights into GC’s anti-inflamatory action 
have revealed that transactivation plays a central role in anti-inflamation, as well10,11. In this context, the 
reduction of GR-mediated transactivation by extracellular molecules can play an important role in the 
improvement of GC’s therapeutic profile.
The H1R is one of the four distinct G-protein coupled receptors that mediate histamine responses in 
the body. The binding of histamine to the H1R results in dissociation of the Gα q/11 subunit from the Gβ γ 
dimer, resulting in the activation of several downstream effectors that lead to the modulation of mem-
brane phosphoinositide metabolism and intracellular calcium levels. Since histamine pro-inflammatory 
effects are largely mediated by its action on H1R, antagonists of this receptor are often used to treat sev-
eral inflammatory-related conditions. Improtantly, many of these clinically used antihistamines are not 
antagonists but inverse agonists, therefore decreasing H1 receptor constitutive activity12,13.
GR activity can be modulated intracellularly at several levels, including protein-protein interaction 
and post-translational modifications, such as, phosphorylation, ubiquitination, acetylation and sumoyla-
tion that affect ligand affinity, receptor localization, transcriptional activity and turnover14. Some previ-
ous studies have explored the possibility to modulate GR signaling through the activation or inhibition 
of GPCR-mediated signaling, demonstrating crossregulation between GR and the β 2-adrenergic, soma-
tostatin and melatonin GPCRs. Mechanistically, epinephrine and norepinephrine enhance GR activity 
via a Gβ γ /PI3K/PKB pathway15, while somatostatin and melatonin suppress GR activity through Gβ γ 
and Gα i proteins respectively16,17. Somehow surprisingly, due to the common therapeutic association 
with GR agonists, no studies have been conducted to characterize the effects of H1R-activated intracel-
lular pathways on GR activity. Hence, the aim of this work was to study how H1R signaling induced by 
its agonists or inverse agonists modulates GR-mediated transcriptional activity induced by its agonists 
dexamethasone and corticosterone. Our results show a complex dual regulation of GR activity by the 
H1R, consisting of a potentiation of dexamethasone effects mediated by G-protein β γ subunits and Jun 
kinase-mediated GR phosphorylation and a parallel inhibition of dexamethasone effect, mediated by 
the canonical Gα q-PLC-Rac pathway. When the H1R is activated by its natural agonist, histamine, the 
simultaneous triggering of both pathways results in a composite activating effect. Conversely, when H1R 
is bound by inverse agonists, the canonical inhibitory Gα q-PLC-Rac pathway is repressed, resulting in 
a potentiation of GR-mediated transcriptional activity. The characterization of signaling mechanisms 
underlying these complex interactions, as well as the discussion of their possible clinical implications, 
are the main purpose of the present work.
Results
Effect of H1R activation on dexamethasone- and corticosterone-induced GR activity. We 
first asked whether histamine-induced H1R signaling could influence GR-mediated transcriptional activ-
ity. Human HEK293T cells were co-transfected with a luciferase reporter plasmid under the control of 
a synthetic promoter regulated by the GR (TAT3-Luc) in combination with plasmids coding for GR 
and H1R and then cells were stimulated with dexamethasone. In this system, while 100 μ M histamine 
induced no significant effect on luciferase activity, the addition of 100 μ M histamine 10 min prior to 
a 24 h dexamethasone treatment induced a two-fold increment in maximal luciferase activity induced 
by dexamethasone alone (2923 ± 169 vs. 6201 ± 344, both expressed in luminescence arbitrary units) 
without affecting dexamethasone’s pEC50 (11.58 ± 0.15 vs. 11.61 ± 0.15) (Fig.  1A). The inhibition of 
G-protein mediated H1R signaling by co-transfection with the G-protein inhibitor RGS2 blocked this 
effect (Fig. 1B). Importantly, histamine did not induce any significant effect on GR mRNA levels (Supp 
Fig. S1). Histamine’s potentiating effect was dose dependent with a pEC50 of 5.4 ± 0.2 (Fig.  2A) and 
partially and dose-dependently blocked by the H1 inverse agonists mepyramine and trans-triprolidine 
(Fig.  2B). Histamine effect was also observed over corticosterone-induced GR activity (Supp Fig. S2). 
These results indicate that G-protein dependent intracellular signaling triggered by histamine-medi-
ated activation of the H1R potentiates GR transcriptional activity induced by synthetic and natural GR 
agonists. However, as we aimed to elucidate the pharmacological interaction of therapeutically relevant 
drugs, we focused our experiments on dexamethasone-induced GR activity only.
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Role of Gα and Gβγ subunits on histamine-mediated potentiation of GR activity. To estab-
lish which of the molecular partners participating in G-protein mediated H1R signaling were responsible 
of the observed potentiation of GR activity, we co-transfected HEK293T cells with the alpha subunit 
of the G-transducin protein (Gα t). This experimental approach is commonly used to reveal the role of 
Gβ γ subunits on downstream effectors, based on their sequestration induced by Gα t overexpression18. 
To evaluate the appropriate transfection and expression levels of transducin, we used its known effect 
on carbachol-induced pERK levels18. For this, HEK293T cells were co-transfected with transducin or 
a control plasmid and a muscarinic M1 receptor coding plasmid and then stimulated with 10 μ M car-
bachol and pERK levels were measured. As expected, transducin co-transfection precluded carbachol’s 
action on pERK activity (Supp Fig. S3). Remarkably, Gα t overexpression was associated with a switch in 
histamine’s effects from potentiation to repression of dexamethasone-induced GR activity (Fig. 3). This 
effect was dependent of the amount of Gα t coding plasmid transfected, suggesting that the effect of Gα T 
is significantly augmented when plasmid concentration is increased, overall indicating a specific effect 
of Gα t transfection (Fig.  3 inset). These observations indicate the existence of a dual regulatory effect 
of H1R-mediated signaling on GR activity, a dominating potentiating effect and a secondary inhibitory 
effect, revealed when Gβ γ subunits were sequestered. Based on these observations, we aimed to further 
identify signaling partners involved in both pathways.
To assess which Gβ and Gγ subunits may be involved in histamine’s effects on GR activity, HEK293T 
cells were co-transfected with Gβ 2 and three different Gγ subunits, which expression was verified by 
fluorescence microscopy and did not affect GR expression levels (Supp Fig. S4A and S4B). We found that 
when the subunits combinations Gβ 2γ 5 and Gβ 2γ 11were co-expressed, histamine’s effect was increased 
(Fig.  4A). This potentiation of histamine’s effect was not observed with the other Gβ γ combination 
assayed. These results suggest the existence of a mechanism involved in histamine’s potentiation of GR 
activity, engaging specific Gβ γ subunits, including Gβ 2γ 5 and Gβ 2γ 11.
Signaling networks activated by G-proteins are very integrated and many downstream effectors have 
been described. PI3K plays an important role in Gβ γ signaling and PI3K also modulates GR activity15. 
However, in our system, both PI3K inhibitors, LY294002 and wortmannin, had no effects on histamine 
modulation (Fig. 4B). Therefore we proceeded to test the effects of other possible signalling partners.
Figure 1. Histamine potentiates dexamethasone-induced GR activity. (A) HEK-293T cells co-transfected 
with the reporter TAT3-Luc and GR coding plasmid were treated for 10 min with 100 μ M histamine (HA) 
or not (− ), and incubated with increasing concentrations of dexamethasone (DEX). Luciferase activity was 
determined as described in the methods section. Curve fitting parameters are detailed in the main text. 
Results are mean+ /− SEM of three independent experiments performed in triplicates. Error bars represent 
SEM. (B) HEK-293T cells co-transfected with TAT3-Luc, GR and H1R constructs were transfected with 
RGS2 or not, as indicated. Luciferase activity was determined as described in the methods section. Results 
are mean+ /− SEM of four independent experiments performed in triplicates. ***p < 0.001.
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Figure 2. Histamine potentiation of GR activity is concentration dependent and blocked by the 
antihistamines mepyramine and trans-triprolidine. (A) HEK-293T cells were co-transfected with the 
reporter TAT3-Luc, GR and H1R codifing plasmids and were preincubated or not with 10 μ M mepyramine 
(Mep) for 10 min, treated for another 10 min with increasing concentrations of histamine and incubated 
with 0.1 nM dexamethasone for 24 h, as indicated. Luciferase activity was determined as described in the 
methods section. Curve fitting parameters are detailed in the main text. Results are mean+ /− SEM of 
three independent experiments performed in triplicates. (B) Co-transfected cells were preincubated with 
indicated concentrations of mepyramine (Mep) or trans-triprolidine (Trip), treated for another 10 min with 
histamine and incubated with dexamethasone for 24 h. Luciferase activity was determined as described in 
the methods section. Curve fitting parameters are detailed in the main text. Results are mean+ /− SEM of 
three independent experiments performed in triplicates.
Figure 3. Overexpression of Gαtransducin switches histamine potentiation into inhibition of GR 
activity. HEK-293T cells co-transfected with TAT3-Luc, GR and H1R coding constructs were transfected or 
not with Gα transducin (Gα t), as indicated. Luciferase activity was determined as described in the methods 
section. Results are mean+ /− SEM of three independent experiments performed in triplicates. Inset: HEK-
293T cells co-transfected with TAT3-Luc, GR and H1R constructs were transfected with different amounts of 
Gα t, and subjected to different treatments, as indicated. Luciferase activity was determined as described in 
the methods section. Results are mean+ /− SEM of three independent experiments performed in triplicates. 
**p < 0.01; ***p < 0.001.
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Involvement of JNK, PLC, PKC, and Rac and Rho small G-proteins on histamine-mediated 
potentiation of GR activity. The c-Jun N-terminal kinase (JNK) is another kinase described both 
as modulator of GR activity and as effector of Gβ γ dimers19,20.
In our system, histamine increased phospho-JNK levels and histamine’s effect was abolished by over-
expression of Gα t, suggesting the involvement of Gβ γ subunits (Fig. 5 and Supp Fig. S5). This makes JNK 
a suitable candidate participating in histamine’s potentiation of GR transcriptional activity. Consistently, 
the JNK inhibitor SP600125 completely abolished histamine’s potentiation of GR response to dexameth-
asone (Fig. 6). Moreover, overexpression of a JNK phosphorylation-deficient mutant, GR-S246A, showed 
that histamine’s effect was dependent on JNK-mediated phosphorylation of the GR (Fig. 6). These results 
indicate that histamine-induced activation of Jun kinase is crucially involved in its potentiating effect 
on GR transcriptional activity. Dexamethasone induces GR phosphorylation at S246, with diverse effects 
on its transcriptional activity21,22. In our hands, the GR mutant S246A showed the same efficacy in the 
gene-reporter assay as the wild type GR, indicating that dexamethasone-induced GR phosphorylation 
at S246 had little, if any, effect on its transcriptional activity in our system (Fig. 6). These observations 
suggest that the minor effects we detect in transcriptional activity may be related to intrinsic properties 
in the cell lines we used in our studies and/or with the sensitivity of our detection method or other 
technical limitations.
Previous observations have shown that after JNK activation by overexpression of its direct activa-
tor MKK7, JNK-mediated GR phosphorylation results in a decrease of GR-dependent transcriptional 
activity20,23. However, these effects are dependent on the promoter-context, since JNK activation has 
opposite effects on TAT3- and MMTV-driven transcriptional activity24. We assessed histamine’s effect on 
MMTV-driven transcriptional activity induced by dexamethasone. In our hands, histamine also poten-
tiated dexamethasone-induced expression of a MMTV-driven luciferase reporter, and this effect was 
hampered by overexpression of GR-S246A, suggesting again involvement of JNK. To evaluate the possi-
ble influence of the cellular context, we also performed experiments in HeLa cells, which were originally 
used to characterize the effect of JNK on GR activity. Again, histamine potentiated GR activity on both 
TAT3- and MMTV-driven luciferase reporter systems (Supp Fig. S6). Together, these results suggest that 
histamine-induced JNK activation may take place by alternative, yet uncharacterized intracellular path-
ways that do not engage MKK7 directly25,26. Overall, previous work and ours show the complexity of the 
impact of S246 phosphorylation on GR activity. However, the exact characterization and disambiguation 
of this complex effects escapes the aim of our work at this point.
Finally, we tried to characterize signaling partners involved in the inhibitory pathway, focusing on 
Gα . Using the specific inhibitors U73122 and GF109203X, we conclude that PLC but not PKC may be 
Figure 4. Gβ2γ5 and Gβ2γ11, but not Gβ2γ2 or PI3K are involved in histamine modulation of GR 
activity. (A) HEK-293T cells co-transfected with TAT3-Luc, GR and H1R coding constructs were transfected 
with β 2 and γ 2; β 2 and γ 5; β 2 and γ 11 or not, and subjected to indicated treatments. Luciferase activity was 
determined as described in the methods section. Results are mean+ /− SEM of at least three independent 
experiments performed in triplicates. **p < 0.01. (B) HEK-293T cells were co-transfected with TAT3-Luc, 
GR and H1R coding constructs and were treated with 2 μ M LY294002 or 50 nM wortmannin 30 min prior 
to indicated treatments. Luciferase activity was determined as described in the methods section. Results are 
mean+ /− SEM of at least three independent experiments performed in triplicates.
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implicated in histamine’s inhibitory effect on GR transcriptional activity (Fig.  7A). Small G-proteins, 
such as Rac and Rho, have been characterized as downstream effectors of H1R signaling27. To evaluate 
their possible role in H1R modulation of GR activity, we used Rac and Rho GEFs Prex1 and p115, as 
activators, and Rac N17 and C3 exoenzyme, as Rac and Rho inhibitors, respectively. We found that Rac 
activation reduced histamine’s potentiation of GR activity. Consistently, the dominant negative mutant 
Rac N17 enhanced histamine’s effect (Fig 7B). Conversely, expression of p115 Rho-GEF or C3 exoenzyme 
had no detectable effect on histamine’s potentiation of GR activity (Fig.  7C), indicating that Rho does 
not participate in this process.
Figure 5. Histamine increases pJNK levels in a Gβγ dependent manner. (A) HEK-293T cells were 
transfected with a H1R coding plasmid and co-transfected or not with Gα transducin and were subjected to 
100 μ M histamine treatment for 10 minutes. A cropped section of the membrane ranging from 40 to 60 kDa 
(upper panel) or 30 to 40 kDa (lower panel) of a representative experiment is shown. Full-length blots are 
provided in Supplementary Fig. 5. (B) Densitometric analysis was performed with ImageJ as described in 
the methods section. Results are mean+ /− SEM of four independent experiments performed. **p < 0.01.
Figure 6. JNK impairment blocks histamine modulation of dexamethasone-induced GR activity. HEK-
293T cells were co-transfected with TAT3-Luc and H1R coding constructs and were co-transfected with GR 
and incubated with 10 μ M SP600125 for 30 min or not, or were co-transfected with GR-S246A, as indicated, 
and then subjected to treatments. Luciferase activity was determined as described in the methods section. 
Results are mean+ /− SEM of three independent experiments performed in triplicates. ***p < 0.001.
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Effect of antihistamines on glucocorticoid-induced gene transactivation and transrepres-
sion. To further evaluate the possible implications of our observations for a clinical scenario involv-
ing the pharmacological association of a GR agonist and an antihistamine, we studied the effect of two 
clinically relevant H1 inverse agonists, mepyramine and trans-triprolidine, on dexamethasone-induced 
GR transcriptional activity. We found that both antihistamines dose-dependently potentiated 
dexamethasone-induced transcriptional activity (from 11935 ± 1068 to 18317 ± 561 for mepyramine 
and to 16806 ± 632 for trans-triprolidine; Fig. 8A). This potentiating effect induced by the H1R inverse 
agonists on GR activity could be due to a decrease in Gα activity and its downstream inhibitory effectors 
or to an increase in a Gβ γ -mediated pathway. However, the stimulatory activity induced by both inverse 
agonists was not affected by Gα t expression, ruling out the involvement of Gβ γ subunits (Fig. 8B).
Transrepression mechanisms are relevant for the effectiveness of glucocorticoids as anti-inflammatory 
agents. Considering this, we tried to elucidate if the potentiation induced by H1R inverse agonists on 
GR activity was conserved on a IL6 promoter-driven luciferase reporter, typically transrepressed by 
dexamethasone. Luciferase expression was induced by pre-exposing cells to TNFα and then, the effect 
of GR activation was measured. Dexamethasone and mepyramine induced a 30% and 25% decrease 
in luciferase, respectively. Remarkably, when cells were co-incubated with both ligands, a synergistic 
effect was observed resulting in a 75% reduction in luciferase signal (Fig. 9A). This synergism was con-
firmed by a left-shift on dexamethasone concentration-response curve (13.74 ± 0.24 vs. 12.14 ± 0.23) 
(Fig. 9B).
Figure 7. PLC and Rac, but not PKC or Rho are involved in histamine modulation of dexamethasone-
induced GR activity. (A) HEK-293 T cells were co-transfected with TAT3-Luc, GR, and H1R coding 
constructs and were incubated for 30 min with 10 μ M U73122 (PLC inhibitor) or 10 μ M GF109203X (PKC 
inhibitor), and then subjected to indicated treatments. (B) HEK-293 T cells were co-transfected with TAT3-
Luc, GR, and H1R coding constructs and were co-transfected with Rac GEF Prex1 or with the dominant 
negative RacN17 and then subjected to indicated treatments. (C) HEK-293T cells were co-transfected with 
TAT3-Luc, GR, and H1R coding constructs and were co-transfected with Rho GEF P115 or with the Rho 
GAP C3 toxin, and then subjected to indicated treatments. Luciferase activity was determined as described 
in the methods section. Results are mean+ /− SEM of three independent experiments performed in 
triplicates. **p < 0.01; ***p < 0.001.
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Effect of H1R inverse agonists on endogenous inflammation-related gene expression 
induced by GR activation. Next, we aimed to assess whether H1R-mediated potentiation of 
dexamethasone-induced gene expression could be replicated in a pathophysiologically relevant cell sys-
tem, where GR agonists and antihistamines are expected to interact. We used A549 alveolar epithelial 
cells, as a model of alveolar reactivity to noxious stimuli and thus a suitable in-vitro model reflecting 
aspects of pulmonary inflammation28,29, and U937 promonocytic cells, a model of skin sensitization30,31. 
The H1R is expressed in U937 promonocytic cells32,33, however we could not find any report of the 
expression of the H1R in the A549 cells. Therefore, we tested the presence of a functional H1R in A549 
cells by measuring the modulation of intracellular calcium levels. 100 μ M histamine was able to produce 
an intracellular calcium spike that was specifically blocked by preincubation with mepyramine, demon-
strating H1R functionality (Supp Fig. S7). Using these two cellular systems, we assayed the expression 
of three primary genes transactivated by the GR34: GILZ (glucocorticoid induced leucine zipper), THBD 
(thrombomodulin) and SLC19A2 (thiamine transporter 1 or solute carrier family 19 member 2); and the 
typically GR-transrepressed proinflammatory gene COX-2 (cyclooxigenase-2)35.
In A549 cells, dexamethasone increased the expression of the three transactivated genes. However, his-
tamine potentiated only THBD expression (Fig. 10A). In U937 cells, only GILZ expression was induced 
by dexamethasone and this effect was potentiated by histamine (Fig.  10B). These observations suggest 
cell-type and gene-specific effects consistent with previous reports of GR cell type- and gene-specific 
actions36, and indicate that the results obtained in gene reporter assays can not be simply extrapolated 
to all endogenous GR-responsive genes.
However, pre-exposure of A549 and U937 cells to each antihistamine tested, mepyramine, 
trans-triprolidine, cetirizine, chlorpheniramine, or diphenhydramine induced, in all cases, a potentiation 
of dexamethasone-induced THBD and GILZ expression (Fig. 10C, D), confirming that the results obtained 
with luciferase could be of clinical and pharmacological interest. The regulation of COX-2 expression 
could not be evaluated in U937 cells because we were unable to measure any significant effect of TNFα 
on COX-2 expression in this cell line (Supp Fig. S8). However, although dexamethasone by itself only 
minutely decreased TNFα -induced COX-2 expression in A549 cells, pretreatment with trans-triprolidine 
and cetirizine, but not chlorpheniramine or diphenhydramine, potentiated dexamethasone-induced inhi-
bition of COX-2 expression (Fig. 10E). These observations indicate that some H1R inverse agonists are 
able to modulate GR-induced transrepression, as well. In all cases, cetirizine showed the highest efficacy 
Figure 8. Antihistamines potentiate dexamethasone-induced GR activity and the overexpression 
of Gαtransducin does not inhibits their effects. (A) HEK-293T cells co-transfected with the reporter 
TAT3-Luc, GR and H1R coding plasmids were preincubated for 10 min with increasing concentrations of 
mepyramine (Mep) or trans-triprolidine (Trip) and incubated with 0.1 nM dexamethasone for 24 h.  
(B) HEK-293T cells were co-transfected with TAT3-Luc, GR and H1R coding constructs and were 
transfected or not with Gα transducin, as indicated, and subjected to treatments. Luciferase activity 
was determined as described in the methods section. Results are mean+ /− SEM of three independent 
experiments performed in triplicates. *p < 0.05; **p < 0.01; ***p < 0.001.
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in potentiating dexamethasone-induced GR activity. Our observations are thus consistent with previous 
work showing that cetirizine is the most efficacious antihistamine available37.
Discussion
In a number of clinical situations related to inflammatory disease, ligands of both H1R and GR are 
co-administered37,38. However, this drug association has no clear rationale and has arisen from the clini-
cal practice, based on the assumption that there should be an intrinsic benefit in their co-administration, 
due to their anti-inflammatory effects. In this work we studied the consequences of co-treatment with 
clinically relevant antihistamines and glucocorticoids at the molecular level in several in-vitro cellular 
systems. Using these simple systems, we characterized for the first time a synergistic effect between the 
H1R and the GR, with particular focus on GR-induced transcriptional activity.
Our results suggest that activation of the H1R triggers a complex dual regulatory mechanism 
on GR activity, involving both Gα q and Gβ γ subunits. Whereas Gα q has an inhibitory effect via a 
PLC-RAC-mediated pathway, Gβ γ enhances GR activity via JNK. Paradigmatically, when an agonist 
binds to a GPCR, it causes the activation of the trimeric G-protein and its subsequent dissociation 
into Gα and Gβ γ subunits, turning on two downstream pathways. Within this framework, both path-
ways may be equally activated. Thus, when agonists bind to, and activate the H1R, Gα q and Gβ γ are 
simultaneously released. Under these circumstances, the Gβ γ pathway prevails, resulting in an overall 
H1R-mediated potentiation of GR activity. Importantly, other GPCRs, such as the β 2-adrenergic, soma-
tostatin and melatonin receptors, have been shown to modulate GR activity via pathways that, at least 
partially, engage the action of Gβ γ subunits14–16, suggesting this may be a widespread pathway for GPCR/
GR regulatory interactions.
On the other hand, when antihistamines bind to, and inactivate the H1R, a potentiating effect on GR 
activity is observed too, which in this case can be attributed to the inactivation of the Gα q-PLC-RAC 
inhibitory pathway. Thus, the initially paradoxical observation that the natural full agonist as well as the 
inverse agonists potentiate GR transcriptional activity can be explained by a decrease in the Gα q-mediated 
inhibition of GR activity induced by inverse agonists.
Figure 9. Mepiramine potentiates dexamethasone-induced GR transcriptional activity in a 
transrepression gene-reporter system. (A) HEK-293T cells were co-transfected with IL6-Luc, GR and H1R 
coding constructs and were incubated with 2000 UI/ml TNFα for 4 h, and exposed to 10 μM mepiramine 
for 10 min and to 10 nM dexamethasone for 24 h, as indicated. (B) HEK-293T cells were co-transfected 
with IL6-Luc, GR and H1R coding constructs and were incubated with 2000 UI/ml TNFα for 4 h, and then 
exposed to 10 μM mepiramine for 10 min and incubated with increasing concentrations of dexamethasone 
for 24 h. Curve fitting parameters are detailed in the main text. Luciferase activity was determined as 
described in the methods section. Results are mean+ /− SEM of three independent experiments performed 
in triplicates. *p < 0.05; **p < 0.01; ***p < 0.001.
www.nature.com/scientificreports/
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Binding of the GR to simple GREs induces epigenetic mechanisms such as histone acetylation and 
chromatin remodeling and recruits RNA polymerase II by interactions with coactivator molecules, 
which in many cases, have acetyltransferase activity and are part of the cellular epigenetic machin-
ery, finally resulting in transactivation of GC target genes6. Therefore, one intriguing possibility is that 
some of the signaling pathways activated by H1R activation could result in ‘priming’ of GR activity to 
pro-inflammatory genes38, by recruiting (epigenetic) cofactors to specific GR target sites. However, this 
tempting hypothesis escapes the direct aim of this study and requires experimental validation.
Relevant cell types where the signaling convergence identified in our work may be relevant should 
express both H1R and GR, such as endothelial cells, dendritic cells, monocytes, neutrophils, T and B 
Figure 10. Histamine and antihistamines modulate dexamethasone-induced expression of endogenous 
GR-target genes. (A, C) A549 cells and (B, D) U937 cells were incubated for 10 min with 100 μ M histamine 
(HA), 10 μ M mepyramine (MEP), 10 μ M trans-triprolidine (TRIP), 10 μ M cetirizine (CET), 10 μ M 
chlorpheniramine (CHLOR), or 10 μ M diphenhydramine (DIPH), as indicated, and then treated with 
dexamethasone (DEX) for 3 h. (E) A549 cells were incubated with TNFα for 4 h, exposed to 10 μ M trans-
triprolidine (TRIP), 10 μ M cetirizine (CET), 10 μ M chlorpheniramine (CHLOR), or 10 μ M diphenhydramine 
(DIPH), as indicated, and treated with dexamethasone (DEX) for 3 h. GILZ, SLC19A2, THBD, and COX-2 
mRNA levels were quantified by qPCR as described in the methods section. Results are mean+ /− SEM of at 
least three independent experiments performed in triplicates. *p < 0.05; **p < 0.01; ***p < 0.001.
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cells and microglia39,40. The existence of these cell types co-expressing both receptors suggests that our 
findings may have implications for regulation of inflammation in several systems, such as lung, skin and 
brain. However, this point requires further experimental validation.
Although our preliminary characterization of the signaling events triggered by the co-administration 
of antihistamines and glucocorticoids is restricted to simple cellular systems in vitro, granting further 
in vivo validation of the mechanisms described herein, our observations may have implications for the 
understanding of the cellular mechanisms triggered by the widespread clinical use of this drug associ-
ation. Of particular concern, our results indicate that the co-administration of an antihistamine and a 
glucocorticoid agonist may result in a potentiation of the transactivation and transrepression of some 
genes key in the inflammatory response. At the same time, transactivation of GR-target genes which 
may be involved in GC’s side effects at pharmacological concentrations could be induced, indicating 
that adverse effect may be potentiated in vivo as well. This possibility suggests the need of a careful (re)
evaluation of the common coadministration of antihistamines and glucocorticoids in the treatment of 
inflammatory conditions. Some illustrative examples, such as are the treatment of AR and AD, suggest 
that our observations could have clinical implications. A study from 2011 showed that the combination 
of both drugs is the most widely-used option in routine clinical practice to treat all types of AR2, and 
three patents have been recently granted to formulations containing the antihistamine azelastine with 
the synthetic corticosteroids mometasone furoate, ciclesonide and fluticasone propionate3. Likewise, 
concerning AD, the synergistic effects of glucocorticoids and antihistamines have been evaluated in an 
animal model, where olopatadine potentiated the inhibitory effect of prednisolone on the relief of the 
inflammatory symptoms leading to the conclusion that this drug combination is useful to treat AD, 
although the mechanism underlying the synergism was not investigated41.
Different approaches have been used to improve the beneficial/undesired effect ratio in the clinical 
administration of glucocorticoids, going from chemical optimization to development of selective gluco-
corticoid receptor agonists (SEGRAs) assuming that ligands that only induce gene transrepression but not 
transactivation should have a better therapeutic profile. The add-on therapies present another alternative 
to control the side effects associated with corticosteroid administration by combining it with another 
aintiinflamatory drug with a different mechanism of action, allowing a reduction in corticosteroid dose 
and a concomitant reduction in adverse effects, since these are more common in patients receiving high 
corticosteroid doses. In this approach, corticoids are combined for example, with β 2-adrenoreceptor 
agonists, teophylline or anti-leukotrienes42.
In this regard, combination therapy of GC and antihistamines can represent a clinically relevant 
option. Although not experimentally tested in this work, co-treatment with a glucocorticoid and an anti-
histamine might allow reductions in the dose of the glucocorticoid in vivo, which could have beneficial 
effects in the clinic. Suggestively, the potentiating effect of antihistamines on GR transcriptional activity 
described here with two GRE-dependent luciferase gene reporter systems and endogenous GR-responsive 
and inflammation-related genes, resulted in a reduction of the doses of dexamethasone needed to achieve 
the same biological effect. Although some of these effects were cell type and gene-specific, our results 
indicate that under certain circumstances the coadministration of antihistamines could result in the 
reduction of the dexamethasone doses need to reach anti-inflammatory effects. Supporting this hypoth-
esis it has been shown that the antihistamine azelastine can reduce the frequency of administration of 
inhaled corticosteroids without loss of pulmonary function on a clinical trial on patients with chronic 
bronchial asthma43.
In conclusion, the molecular characterization of the interactions between intracellular signaling cas-
cades triggered by activation of the H1R by histamine and its inverse agonists and GR- mediated tran-
scriptional activity presented in this work provides a starting point for understanding and re-evaluating 
the use of antihistamines as add-on drugs in glucocorticoid-mediated anti-inflammatory therapies. 
Further characterization and validation of this interaction at the molecular level, its possible relevance 
and its pharmacokinetic and pharmacodynamics properties in vivo, will help to improve commonly used 
combination therapies.
Materials and Methods
Materials. DMEM medium, antibiotics, phosphate-buffered saline (PBS), bovine serum albumin 
(BSA), histamine dihydrochloride, wortmannin, SP600125, U73122, dexamethasone, cetirizine, chlor-
pheniramine and diphenhydramine were obtained from Sigma. LY294002, mepyramine maleate, 
trans-triprolidine and GF109203X were from Tocris Cookson Inc. (Ballwin, MO). Fetal bovine serum 
(FBS) was purchased from Natocor. All other chemicals were of analytical grade and obtained from 
standard sources.
Plasmid Constructions. pRSV-GR was cloned by Dr. Keith Yamamoto44. pCEFL-H1R and TAT3-Luc 
were previously generated in our laboratory12,45. MMTV-Luc was provided by Dr. A Pecci (IFIBYNE, 
CONICET, UBA) and IL6-Luc was a gift from Prof. Dr. Karolien De Bosscher (VIB Department of Medical 
Protein Research, University of Gent, Belgium). pcDNA3-C3 was granted by Dr. Omar Coso (IFIBYNE, 
CONICET, UBA). pCMV-Myc-PRex1, pcDNA3-RGS2 and pcDNA3-p115 were kindly provided by Dr. 
Marcelo Kazanietz (University of Pennsylvania School of Medicine, Philadelphia), pEGFP-C1-Gβ 2 and 
pEGFP-C1-Gγ 2 were kindly provided by Dr. Tomoshige Kino (DeCherney Lab—Section on Implantation 
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and Oocyte Physiology, National Institutes of Health, Bethesda), pENTR-YFP-Gγ 5 and pcDNA3-
1-YFP-Gγ 11 were a kind gift from Dr. N Gautam (Anesthesiology and Genetics Dpt, Washington 
University School of Medicine, St. Louis). pCEFL-Gα transducin was a kind gift from Dr. Silvio Gutkind 
(Oral and Pharyngeal Cancer Branch, National Institutes of Health, Bethesda), pEYFP-N1-M1R was pro-
vided by Dr. JC Goin (CEFYBO, CONICET, UBA), pcDNA3-HA-GR-S246A was a gift from Dr. Marija 
Krstic-Demonacos (Molecular Medicine. University of Salford, Manchester, UK), and pcDNA3-RacN17 
was kindly provided by Dr. Heidi Welch (Babraham Institute, Cambridge).
Cell culture. HEK293T (human embryonic kidney), HeLa (cervical cancer), and A549 (human pul-
monary) cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM). U937 (human promono-
cytic) cells were cultured in RPMI 1640 medium. All mediums were supplemented with 10% fetal calf 
serum and 5 μ g/ml gentamicin and cells were incubated at 37 °C in humidified atmosphere containing 
5% CO2.
Transfection and reporter gene assays. HEK293T or HeLa cells seeded on 24-well plates were 
co-transfected using the K2 Transfection System (Biontex, Munich, Germany) with the TAT3-Luc, 
MMTV-Luc or IL6-Luc luciferase reporter plasmids and pRSV-GR according to the manufacturer’s 
instructions. In some experiments, cells were also co-transfected with the plasmid constructs indi-
cated in the corresponding figure or an empty vector to maintain an equal amount of total DNA. After 
4h, cells were seeded in 96-well plates, and 24 h later cells were starved overnight and then stimulated 
with diverse agents. After a kinetic assessment, luciferase activity was measured at the optimal time of 
24 h later using the Steady-Glo Luciferase Assay System according to the manufacturer’s instructions 
(Promega Biosciences Inc. San Luis Obispo, CA, USA) using a FlexStation 3 Multi-Mode Microplate 
Reader (Molecular Devices, LLC). Experimental reporter activity was normalized to control activity. No 
differences were observed in results normalized to renilla-luc or to protein expression levels.
RT-PCR and Quantitative real-time PCR. Total RNA was isolated from A549 or U937 cells using 
Quick-Zol reagent (Kalium Technologies) following the manufacturer’s instructions. For the first-strand 
cDNA synthesis, 1 μ g of total RNA was reverse-transcribed using the High Capacity cDNA Reverse 
Transcription kit (AB) with random primers. Quantitative real-time PCR (qPCR) was performed in 
triplicate on the Rotor Gene Q cycler (Qiagen) using the resulting cDNA, the HOT FIREPol EvaGreen 
qPCR Mix Plus (Solis Biodyne) for product detection, and the following primers: human GILZ (glu-
cocorticoid induced leucine zipper; NM_001015881.1) forward, 5′ -AATGCGGCCACGGATG-3′ and 
reverse, 5′ -GGACTTCACGTTTCAGTGGACA-3′ ; THBD (thrombomodulin; NM_000361.2) for-
ward, 5′ -GACCTTCCTCAATGCCAGT-3′ and reverse, 5′ - CCGTTCAGTAGCAAGGAAATG-3′ ; 
SLC19A2 (thiamine transporter 1 or solute carrier family19 member 2; NM_006996.1) forward, 
5′ -TTCTCTGCTGGTCTGTGTGG-3′ and reverse, 5′ -AGCGAGAAGGCATCACTTTC-3′; COX-2 
(cyclooxigenase-2; NM_000963.1) forward 5′ -TTCAAATGAGATTGTGGGAAAATTGCT-3′ and 
reverse 5´-AGATCATCTCTGCCTGAGTATCTT-3´, GR (glucocorticoid receptor; NP_000167.1) 
forward 5′ -TACCCTGCATGTACGACCAA-3′ and reverse 5′ -TCCTTCCCTCTTGACAATGG-3′ ; 
and human β -Actin (β Act) forward, 5′ -GGACTTCGAGCAAGAGATGG-3′ and reverse 
5′ -AGCACTGTGTTGGCGTACAG-3′ . The cDNA was amplified by 45 cycles of denaturing (10 s at 
95 °C), annealing (10 s at 60 °C), and extension (10 s at 72 °C) steps. The specificity of each primer set was 
monitored by analyzing the dissociation curve, and the relative GILZ, THBD or SLC19A2 mRNA quan-
tification was performed using the comparative Δ Δ Ct method using β -Actin as the housekeeping gene.
Western Blot Assay. Cells were lysed in 50 mM Tris-HCl, pH 6.8, 2% SDS, 100 mM 2-mercaptoethanol, 
10% glycerol, and 0.05% bromophenol blue and sonicated to shear DNA. Total cell lysates were resolved 
by 10% SDS-PAGE for pJNK detection, blotted, and incubated with 1 μ g/ml rabbit polyclonal anti-pJNK 
or anti-pERK (Santa Cruz Biotechnology) in PBS containing 0.05% Tween 20. All subsequent washes 
were performed with the same buffer. Reactivity was developed using an anti-rabbit polyclonal antibody 
linked to horseradish peroxidase (Santa Cruz Biotechnology) and enhanced chemiluminescence reagents 
following the manufacturer’s instructions (Amersham Biosciences). Thereafter, membranes were stripped 
with stripping buffer before being reprobed with anti-GAPDH (Santa Cruz Biotechnology) to ensure 
equal loadings.
Data Analysis. Statistical analysis was performed through GraphPad Prism 5.0 (GraphPAD Software 
for Science, San Diego, CA, USA). Results are expressed as mean ± SEM. Parametric statistical analysis 
was performed using one- or two-way ANOVA, followed by Bonferroni post hoc multiple comparisons. 
Differences were considered significant at p < 0.05.
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